Sidoti Csr Issues Optimistic Estimate for USNA Earnings

USANA Health Sciences, Inc. (NYSE:USNA) – Stock analysts at Sidoti Csr upped their Q1 2026 earnings per share estimates for shares of USANA Health Sciences in a note issued to investors on Tuesday, December 24th. Sidoti Csr analyst A. Lebiedzinski now expects that the company will post earnings per share of $0.91 for the quarter, up from their prior estimate of $0.82. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2026 earnings at $0.88 EPS and Q3 2026 earnings at $0.91 EPS.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $200.22 million during the quarter, compared to analysts’ expectations of $208.45 million. During the same quarter in the prior year, the company earned $0.59 EPS.

A number of other research firms have also commented on USNA. StockNews.com upgraded shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, December 19th. DA Davidson upgraded shares of USANA Health Sciences to a “hold” rating in a report on Friday, December 20th.

USANA Health Sciences Price Performance

Shares of USNA stock opened at $36.66 on Wednesday. The business has a 50-day moving average of $37.89 and a 200 day moving average of $40.04. USANA Health Sciences has a 1-year low of $31.44 and a 1-year high of $54.81. The stock has a market capitalization of $698.74 million, a PE ratio of 12.95, a P/E/G ratio of 1.25 and a beta of 0.89.

Hedge Funds Weigh In On USANA Health Sciences

Large investors have recently modified their holdings of the stock. Safe Harbor Fiduciary LLC purchased a new stake in shares of USANA Health Sciences during the third quarter valued at approximately $30,000. KBC Group NV boosted its stake in USANA Health Sciences by 96.6% during the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after purchasing an additional 519 shares during the last quarter. Centiva Capital LP bought a new stake in shares of USANA Health Sciences in the 3rd quarter worth $213,000. BOKF NA raised its stake in shares of USANA Health Sciences by 99.4% in the second quarter. BOKF NA now owns 5,526 shares of the company’s stock worth $250,000 after purchasing an additional 2,755 shares during the last quarter. Finally, Quest Partners LLC bought a new position in shares of USANA Health Sciences during the third quarter valued at $250,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Insider Activity at USANA Health Sciences

In other news, Director Gilbert A. Fuller sold 675 shares of the company’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $37.71, for a total value of $25,454.25. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.33% of the stock is owned by corporate insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.